01Approach to the Critical Patient/attcp49

Immediate priorities

›Airway and respiratory threats

›Bulbar weakness compromising airway

›Diminished or absent gag reflex

›Inability to handle secretions

›Gurgling or wet voice quality

›Respiratory failure indicators

›FVC < 30% predicted or < 1 L

›Negative inspiratory force less than -25 cmH2O

›SpO2 declining or PaCO2 rising

›If respiratory failure or inability to protect airway, proceed to intubation

›Prepare for difficult airway due to bulbar weakness

›Avoid succinylcholine if prolonged weakness suspected

›Neurotoxin and hemodynamic threats

›Autonomic dysfunction assessment

›Orthostatic hypotension

›Fixed dilated pupils with no light reflex

›Paralysis progression pattern

›Descending symmetric weakness

›Cranial nerve involvement preceding limb weakness

›Contact state public health authority and CDC immediately

›Heptavalent botulism antitoxin (HBAT) release is time-critical

›24-hour CDC Emergency Operations: 770-488-7100

Monitoring and targets

›Respiratory monitoring bundle

›Serial pulmonary function testing every 4 to 6 hours

›Forced vital capacity trend

›Negative inspiratory force trend

02History/hx71

Exposure and onset

›Food exposure history

›Home-canned or home-preserved foods

›Low-acid vegetables, fish, meats

›Garlic in oil preparations

›Vacuum-packed foods

›Commercial or artisanal products

›Fermented fish products (Type E risk)

›Onset timing from exposure

›Typically 12 to 36 hours after foodborne ingestion

›Range 6 hours to several days depending on toxin load

›Wound exposure history

›Injection drug use

›Black tar heroin strongly associated with wound botulism

›Subcutaneous and intramuscular injection sites

›Traumatic wound with devitalized tissue

›Anaerobic environment permitting C. botulinum growth

›No food exposure needed

Classic symptom complex

›The four Ds of bulbar onset

›Diplopia

›Often earliest symptom

›Disconjugate gaze on exam

›Dysarthria

›Slurred or nasal speech

›Progressive worsening

›Dysphagia

›Difficulty swallowing liquids before solids

03Physical Exam/exam65

Vitals and general

›Vital sign pattern

›Temperature

›Afebrile is characteristic

›Fever prompts wound infection or aspiration pneumonia search

›Blood pressure

›Orthostatic hypotension from autonomic dysfunction

›Measure supine and standing

›Respiratory rate

›Tachypnea as early respiratory failure marker

›Paradoxical breathing pattern with diaphragm weakness

›General appearance

›Alert and oriented with profound weakness

›Preserved cognition despite paralysis

›Ptotic facies and symmetric facial droop

›Voice character

›Nasal or hypophonic voice

›Wet or gurgling quality indicating pooled secretions

Cranial nerve examination

›Ocular findings

›Bilateral ptosis

›Often asymmetric early

›Progresses to complete ptosis

›Pupillary changes

›Mydriasis with sluggish or absent light reflex

›Fixed dilated pupils in severe cases

›Extraocular movement abnormalities

›Disconjugate gaze

04Differential Diagnosis/ddx62

Immediate life threats and mimics

›Ascending paralysis syndromes

›Guillain-Barre syndrome

›ICD-10 G61.0

›Ascending pattern versus descending botulism

›CSF albuminocytologic dissociation in GBS

›Sensory involvement common in GBS

›Miller-Fisher variant of GBS

›Ophthalmoplegia, ataxia, areflexia triad

›Anti-GQ1b antibody positive

›Ascending distribution

›Neuromuscular junction disorders

›Myasthenia gravis

›ICD-10 G70.01

›Fatigable ptosis and diplopia

›Positive edrophonium test

›Repetitive stimulation shows decremental response

›Lambert-Eaton myasthenic syndrome

›ICD-10 G73.1

›Presynaptic calcium channel disorder

›Incremental response on repetitive stimulation at high frequency

›Autonomic features overlap with botulism

›Central nervous system pathology

›Brainstem stroke

›ICD-10 I63.9

›Unilateral findings typical

›Asymmetric cranial nerve deficits

›MRI diffusion restriction differentiates

05Laboratory Tests/lt40

Confirmatory toxin testing

›Botulinum toxin detection

›Serum mouse bioassay via CDC or state lab

›Reference standard for toxin identification

›Sensitivity approximately 70% in foodborne cases

›Results may take 1 to 3 days

›Stool culture and toxin assay

›Higher yield in infant and intestinal botulism

›Culture for C. botulinum in addition to toxin detection

›Collect minimum 25 to 50 g stool

›Gastric aspirate or vomitus

›Submit if ingestion within past 24 hours

›Identify toxin type for epidemiologic investigation

›Wound culture (wound botulism)

›Anaerobic culture from wound or wound swab

›C. botulinum isolation confirms diagnosis

›Correlate with EMG findings

Labs to differentiate and support

›CSF analysis

›Normal protein and cell count in botulism

›Albumincytologic dissociation elevates suspicion for GBS

›Perform when ascending pattern or GBS suspected

›Opening pressure and cell count

›Pleocytosis absent in botulism

›Normal in typical cases

›Serum and metabolic labs

›Complete blood count

›Leukocytosis suggests wound infection or aspiration pneumonia complication

06Diagnostic Tests/dt69

Scoring Systems

›Clinical severity classification

›Mild botulism

›Cranial nerve involvement only

›No limb weakness

›No respiratory compromise

›Moderate botulism

›Limb weakness present

›No respiratory failure

›Ambulatory or borderline ambulatory

›Severe botulism

›Respiratory failure requiring mechanical ventilation

›Complete flaccid paralysis

›ICU care required

›No validated bedside scoring tool exists for botulism severity

›Clinical respiratory thresholds used in practice

›FVC < 1 L or < 30% predicted

›NIF worse than -25 cmH2O

›ACEP Level C recommendation to use clinical gestalt and pulmonary function trends

MRI

›Brain MRI

›Role in differential diagnosis

›Excludes brainstem stroke with DWI sequences

›Normal in uncomplicated botulism

›Indications

›Asymmetric cranial nerve findings

›Altered mental status inconsistent with botulism

›Atypical or unilateral presentation

07Disposition/dispo33

Admission criteria

›Hospitalization required for all suspected botulism

›ICU admission indications

›Any respiratory compromise or declining FVC

›Bulbar weakness with aspiration risk

›Moderate or severe classification

›Floor admission indications

›Mild disease with stable FVC

›Close monitoring for progression required

›No safe outpatient management for suspected botulism

›Transfer criteria

›Transfer to center with ICU and antitoxin capability

›HBAT stored at CDC Strategic National Stockpile

›Coordinate antitoxin release before or during transfer

›Prolonged ventilatory support anticipated

›Transfer to facility capable of long-term mechanical ventilation

›Rehabilitation planning from early in course

Specialist consultation plan

›Required consultations

›Infectious disease

›Antitoxin coordination with CDC

›Wound management for wound botulism

›Neurology

›EMG and NCS interpretation

›Longitudinal follow-up of neurologic recovery

›Critical care or pulmonology

›Ventilator management

›Weaning strategy planning

08Treatment/t86

Heptavalent botulism antitoxin

›HBAT indication and timing

›All suspected botulism cases in adults and children over 1 year

›Do not wait for laboratory confirmation

›Clinical diagnosis is sufficient

›Administer as early as possible

›Greatest benefit within 24 hours of symptom onset

›Benefit demonstrated up to 2 days from onset

›Improvement begins median 2.4 days after antitoxin administration

›HBAT dosing and administration

›Standard adult dose: one vial IV

›Dilute 1:10 in 0.9% NaCl or 5% dextrose

›Infuse over 60 minutes initially

›Increase rate if tolerated after first 30 minutes

›Premedication for infusion reactions

›Diphenhydramine 50 mg IV or PO 30 minutes before

›Consider corticosteroid premedication if high allergy risk

›Obtain from CDC via state health department

›Call CDC Emergency Operations: 770-488-7100

›24-hour availability from Strategic National Stockpile

›Efficacy data

›Earlier administration associated with shorter ICU stay

›Median ICU stay 10 days with antitoxin

›Motor strength recovery median 4.8 days after antitoxin

›Neutralizes circulating toxin only

›Does not reverse established neuronal binding

›Prevents further progression when given early

›ACEP Level B recommendation for early antitoxin in suspected botulism

Infant botulism treatment

›Human botulinum immune globulin intravenous (BIG-IV)

›Indicated for infant botulism under 12 months

›HBAT is not indicated for infants

›BIG-IV (BabyBIG) specifically indicated for infant botulism

›Single dose 50 mg/kg IV

›Contact California Department of Public Health: 510-231-7600

›Reduces hospital stay from median 5.7 to 2.6 weeks

›Class I recommendation based on controlled trial evidence

Respiratory management

›Intubation thresholds

›Elective intubation when trajectory is declining

›FVC less than 1 L or less than 30% predicted

›NIF worse than -25 cmH2O

›Before acute decompensation preferred

›Rapid sequence intubation considerations

›Succinylcholine may cause prolonged effect if concurrent paralysis

›Rocuronium preferred if neuromuscular blocker needed

›Dose: rocuronium 1.2 mg/kg IV for RSI

›Ventilator management

›Lung protective strategy

›Tidal volume 6 to 8 mL/kg ideal body weight

›PEEP titrated to oxygenation

›Prolonged mechanical ventilation anticipated

›Median ventilation duration 7 to 8 weeks in severe cases

›Tracheostomy planning for extended ventilation

›Weaning assessment

›Serial FVC and NIF monitoring

›Spontaneous breathing trials when clinical improvement evident

Supportive and wound management

›Wound botulism specific

›Wound debridement

›Surgical exploration and debridement of infected wound

›Anaerobic environment elimination

›Antibiotics for wound botulism

›Penicillin G 3 to 4 million units IV every 4 hours

›Metronidazole 500 mg IV every 8 hours as alternative

›Avoid aminoglycosides which may worsen neuromuscular blockade

›Gastrointestinal decontamination

›Gastric lavage for early foodborne presentation

›Within hours of ingestion when feasible

›Airway protection mandatory before lavage

›Enemas for stool evacuation

›Removes toxin-containing stool

›Supported by expert consensus

›Nutritional support

›NPO with aspiration risk

›Nasogastric or nasojejunal feeding tube

›Parenteral nutrition if enteral route not feasible

›Early nutritional consultation

›Prolonged ICU course anticipated

›Caloric needs in mechanically ventilated patients

›Autonomic support

›Urinary retention management

›Foley catheter placement

›Monitor urine output

›Ileus management

›Bowel regimen and prokinetics with caution

›Avoid opioids that worsen constipation

›DVT prophylaxis in paralyzed patients

›Unfractionated heparin 5000 units SC every 8 to 12 hours

›Mechanical prophylaxis with pneumatic compression

09Special Populations/sp64

Pregnancy

›Pregnancy considerations

›Antitoxin safety

›HBAT is equine-derived and carries risk of anaphylaxis and fetal exposure

›Risk of untreated botulism exceeds antitoxin risk

›Administer HBAT after risk-benefit discussion with obstetrics

›Respiratory monitoring

›Decreased diaphragmatic reserve at term

›Lower threshold for intubation in third trimester

›SpO2 target >= 95% for fetal oxygenation

›Fetal and neonatal considerations

›Vertical toxin transmission

›Not documented; botulinum toxin does not cross placenta

›Maternal paralysis poses delivery and airway risk

›Fetal monitoring

›Continuous fetal heart rate monitoring in viable gestation

›Obstetrics team involvement mandatory

›Infant at delivery

›Born to mother with foodborne botulism is not affected by toxin

›Screen for honey or spore exposure postnatally

Geriatric

›Older adult considerations

›Atypical presentation risk

›Baseline dysphagia and constipation may mask early symptoms

›Weakness attributed to frailty or deconditioning

›High index of suspicion required

›Comorbidity burden

›Aspiration pneumonia complication more common

10Background/b77

Epidemiology

›Incidence and type distribution

›United States approximately 100 to 200 cases annually

›Foodborne botulism 25% of cases

›Infant botulism approximately 70% of cases

›Wound botulism increasing due to injection drug use

›Type A predominates in western United States

›Most severe form with highest mechanical ventilation rate

›Type E associated with seafood products and Alaska cases

›Outbreaks are sentinel events

›Single case triggers public health investigation

›Cluster cases suggest common food source

›Mortality and morbidity

›Case fatality rate under 5% in modern era with supportive care

›Historical case fatality 25% before intensive care

›Mortality driven by respiratory failure complications

›Prolonged hospitalization

›Median ICU stay 10 to 15 days

›Median hospital stay 15 to 25 days

›Recovery may extend months for severe cases

›Wound botulism mortality approximately 10%

›Related to delayed diagnosis and injection drug use comorbidities

Pathophysiology

›Toxin mechanism

›C. botulinum produces seven toxin serotypes A through G

›Types A B E and F cause human disease

›Type A most common and most severe in adults

›Presynaptic neuromuscular junction blockade

›Toxin is a zinc-dependent endopeptidase

›Cleaves SNARE proteins required for acetylcholine vesicle fusion

›Prevents acetylcholine release at motor nerve terminals

›Cholinergic blockade at autonomic synapses

›Parasympathetic blockade causes mydriasis and dry mouth

›Sympathetic involvement contributes to autonomic instability

›Recovery mechanism

›New axonal sprouting and neuromuscular junction remodeling

›Slow process taking weeks to months

›Recovery begins after toxin clears and new synapses form

›Antitoxin prevents further toxin binding only

›Cannot reverse toxin already bound to nerve terminals

›Early administration before toxin fully bound is critical

›Clinical type distinctions

›Foodborne botulism

›Preformed toxin ingested from contaminated food

›Toxin absorbed in proximal small intestine

›Wound botulism

›In situ toxin production from C. botulinum in wound

›Onset typically 4 to 14 days after wound inoculation

›Infant botulism

›Intestinal colonization produces toxin continuously

›Not a toxin ingestion syndrome

›Iatrogenic botulism

›Overdose or spread from therapeutic botulinum toxin injections

›Rare but reported

Therapeutic Considerations

›Antitoxin strategy principles

›Treat on clinical suspicion not laboratory confirmation

›Laboratory confirmation takes 1 to 3 days

›Delay worsens outcomes

›Earlier is better evidence base

›Antitoxin effectiveness diminishes as more toxin binds

›CDC guidelines recommend administration within 24 hours of symptom onset

›One-time dosing simplifies management

›Single vial HBAT covers all seven toxin serotypes

›Heptavalent design obviates need for serotype identification

›Antibiotic principles for wound botulism

›Antibiotics do not treat toxin-mediated disease

›Antibiotics for wound botulism target C. botulinum colonization

›Not indicated for foodborne or infant botulism

›Aminoglycoside avoidance

›Aminoglycosides enhance presynaptic blockade

›Can precipitate acute respiratory failure

›Avoid gentamicin, tobramycin, and amikacin

›Supportive care as primary intervention

›Mechanical ventilation is life-saving

›Intensive care and mechanical ventilation reduced mortality from 25% to under 5%

›Long-term ventilation planning required

›Rehabilitation importance

›Physical and occupational therapy during prolonged hospitalization

›Speech therapy for dysphagia recovery assessment

11Patient Discharge Instructions/pdi40

copy discharge instructions

›Botulism recovery home care

›Recovery takes weeks to months

›Weakness and fatigue are expected

›Full recovery is expected for most patients

›Activity restrictions

›No driving until vision and strength fully recovered

›Avoid activities requiring full strength until cleared by physician

›Diet and swallowing

›Follow swallowing therapy instructions

›Soft or modified texture diet if swallowing is still affected

›Take small sips and small bites

›Medications after discharge

›Take all prescribed medications as directed

›Do not stop any medication without calling your doctor

›No specific botulism medication taken at home

›Antitoxin was given in hospital

›Warning signs to return to the emergency room

›Difficulty breathing or shortness of breath

›Trouble swallowing or choking on food or fluids

›Worsening weakness or new weakness

›Blurred or double vision returning

›Drooping eyelids worsening

›Inability to speak clearly

›Difficulty urinating

›Fever over 38.5 degrees Celsius

›Food safety after botulism

›Do not eat or share the implicated food

12References/r27

Guidelines and key sources

›Guideline sources

›CDC botulism clinical guidelines and antitoxin access protocols

›Centers for Disease Control and Prevention, Emergency Operations Center

›https://www.cdc.gov/botulism

›JAMA bioterrorism consensus statement

›Arnon SS et al, JAMA 2001, botulinum toxin as biological weapon

›Infectious Diseases Society of America laboratory guidelines 2024

›Miller JM et al, Clinical Infectious Diseases 2024

›Key clinical studies

›Shapiro RL, Hatheway C, Swerdlow DL

›Botulism in the United States: clinical and epidemiologic review

›Annals of Internal Medicine 1998

›Rao AK et al, Clinical Infectious Diseases 2017

›Clinical characteristics and ancillary test results among patients with botulism United States 2002-2015

›Yu PA et al, Clinical Infectious Diseases 2017

›Safety and improved clinical outcomes in patients treated with HBAT

›Richardson JS et al, Clinical Infectious Diseases 2020

›Safety and clinical outcomes of HBAT for confirmed or suspected botulism

›Chalk CH et al, Cochrane Database of Systematic Reviews 2019

›Medical treatment for botulism

›Beliveau M et al, Clinical Pharmacology and Therapeutics 2022

›Exposure-response modeling to support HBAT dosing

›Coding standards

›ICD-10 A05.1 botulism foodborne

›ICD-10 A48.3 wound botulism

›ICD-10 A48.51 infant botulism

›SNOMED CT 414093002 botulism disorder

Evidence & Review

Evidence & Review